Mineralocorticoid Receptor Antagonists for Retinal Fluid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fluid accumulation in and under the retina, particularly in conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration, is not effectively managed by current treatments, which often lead to severe side effects due to the molecular mechanisms underlying retinal hydration remaining unexplored.
Innovation Solution
The use of mineralocorticoid receptor (MR) antagonists, including anti-sense oligonucleotides, small interfering RNAs (siRNAs), and ribozymes, to inhibit MR gene expression, which regulates aquaporin and Kir4.1 expression in Müller glial cells, thereby addressing fluid accumulation issues associated with metabolic perturbations and retinal diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional glucocorticoid treatments are used to manage fluid accumulation in the retina, then fluid accumulation is reduced, but severe side effects occur
Solution Approach 1:
The patent changes the molecular target parameter from glucocorticoid receptors to mineralocorticoid receptors. By using MR antagonists instead of glucocorticoids, the treatment achieves fluid reduction through a different molecular pathway (modulating aquaporin and Kir4.1 expression) that avoids the severe side effects associated with traditional glucocorticoid therapy.
2Quantity of substance
If current treatments for retinal fluid accumulation are used, then some fluid reduction is achieved, but the molecular mechanisms remain unexplored leading to ineffective management
Solution Approach 1:
The patent incorporates feedback by modulating the expression of specific ion channels (Kir4.1) and water channels (aquaporins) in Müller glial cells. This targeted approach allows for precise control of retinal hydration based on the molecular mechanisms underlying fluid accumulation, improving reliability of treatment management.
3Object-affected harmful factors
If MR antagonists are used to treat retinal fluid accumulation, then fluid accumulation is reduced with fewer side effects, but the treatment targets previously unexplored molecular mechanisms
Solution Approach 1:
The patent uses MR antagonists as intermediary molecules that block mineralocorticoid receptor activation. This intermediary approach modulates the expression of downstream targets (aquaporins and Kir4.1 channels) without directly interfering with the complex molecular pathways, thereby reducing side effects while managing the underlying molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces fluid accumulation in the retina by modulating ion and water channels, offering a novel treatment for conditions like diabetic retinopathy and age-related macular degeneration while minimizing the severe side effects of traditional glucocorticoid treatments.
Implementation Method 1
Ion channels and aquaporins are differentially expressed in retinal cells, and play important roles in ion and water movements that are crucial for adequate control of retinal hydration
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.